Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

PHASE3RecruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Postoperative Urinary Tract Infection
Interventions
DRUG

Tamsulosin

"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."

OTHER

Control Group

A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.

Trial Locations (3)

30308

RECRUITING

Emory Saint Joseph's Hospital, Atlanta

RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital (EUH), Atlanta

All Listed Sponsors
collaborator

ABRAHAM J & PHYLLIS KATZ FOUNDATION

UNKNOWN

lead

Emory University

OTHER